The trial will now include a broader population, such as adults over 65, individuals with high-risk co- morbidities, and those with compromised immune systems. This expansion aims to demonstrate the drug's effectiveness across diverse groups, potentially increasing its market appeal. Currently, CDTX is priced at $88.58, reflecting a 20.53% increase, or $15.09 rise. The stock has fluctuated between $77 and $90.64 today, with the latter being its highest price in the past year. CDTX has a market cap of $2.25 ...